Intraoperative use of spectroscopic detection of protoporphyrin IX from oral 5-aminolevulinic acid on malignant skin tumors during Mohs surgery
Phase 2
- Conditions
- basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)
- Registration Number
- JPRN-UMIN000017234
- Lead Sponsor
- Hokkaido University Graduate School of Medicine Department of Dermatology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
the patient with porphilia
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method a resection method using 5-ALA-mediated PDD as a treatment to completely remove malignant skin tumors
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does 5-aminolevulinic acid induce protoporphyrin IX accumulation in basal cell carcinoma and squamous cell carcinoma during Mohs surgery?
What is the comparative efficacy of 5-ALA spectroscopic detection versus standard Mohs techniques for skin tumor margins?
Which biomarkers correlate with protoporphyrin IX fluorescence response in patients undergoing 5-ALA-guided Mohs surgery for BCC/SCC?
What adverse events were reported in the JPRN-UMIN000017234 Phase II trial using 5-ALA for Mohs surgery in BCC/SCC?
Are there combination therapies with 5-ALA and other photosensitizers that enhance tumor detection during Mohs surgery for BCC and SCC?